icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   7 Trials   7 Trials   4331 News 


«12...678910111213141516...5051»
  • ||||||||||  Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
    Clinical, Journal:  The clinical black, white, and gray lessons. (Pubmed Central) -  Mar 23, 2022   
    Consistent findings across multiple trials help strengthen the evidence for specific endpoints or sub-populations, and these findings must be included in guidelines. Large prospective cohort studies with diligent study protocols are warranted in the future to resolve unanswered dilemmas.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Trial completion date, Trial primary completion date:  A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid (clinicaltrials.gov) -  Mar 21, 2022   
    P4,  N=3, Recruiting, 
    Large prospective cohort studies with diligent study protocols are warranted in the future to resolve unanswered dilemmas. Trial completion date: Jan 2022 --> Jul 2022 | Trial primary completion date: Jan 2022 --> Jul 2022
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  High-dose Omega-3 for cardiovascular prevention, a bad idea? (Pubmed Central) -  Mar 17, 2022   
    An increased risk of atrial fibrillation was observed in both studies. The European 2021 cardiovascular prevention guidelines propose to consider high-dose ethyl icosapent on a case-by-case basis in patients with hypertriglyceridemia.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Review, Journal:  Omega-3 Polyunsaturated Fatty Acids-Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review). (Pubmed Central) -  Mar 15, 2022   
    However, despite recent evidence in the prevention of cardiovascular disease by a relatively high dose of icosapent ethyl (EPA derivative), there is still a paucity of data describing the exact mechanisms of n-3 PUFAs, including the role of their particular metabolites. The purpose of this review is to discuss the effects of n-3 PUFAs at several levels of the cardiovascular system, including controversies.
  • ||||||||||  Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
    Review, Journal:  Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. (Pubmed Central) -  Mar 9, 2022   
    Two recent trials of mixed formulations - STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) and OMEMI (Omega-3 fatty acids in Elderly patients with Myocardial Infarction) - studied contemporarily treated patients with mixed EPA + DHA formulations at higher doses than before and showed no benefit, thus adding valuable information to our overall understanding of this evolving therapeutic class. In this review, we contextualize the findings of STRENGTH and OMEMI within the existing omega-3 FA clinical trial landscape and look ahead to how future trials can inform existing knowledge gaps, particularly with regards to the applicability of these agents within the primary prevention realm.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Analysis of Ischemic Stroke Cases Eligible for Novel Treatment of Hypertriglyceridemia (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2804;    
    About 5% of patients on a statin qualified for IPE. This population was more likely to have DM, HTN and CAD.  Stroke patients newly initiated on a statin should have follow-up TG measurement to assess eligibility for HTG treatment.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal, HEOR:  Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. (Pubmed Central) -  Mar 3, 2022   
    Compared with standard care, IPE had a 58.4% lifetime probability of costing less and being more effective when using SSR cost and an 89.4% probability of costing less than $50 000 per QALY gained when using SSR cost and a 72.5% probability of costing less than $50 000 per QALY gained when using WAC. This study suggests that, both in-trial and over the lifetime, IPE offers better cardiovascular outcomes than standard care in REDUCE-IT participants at common willingness-to-pay thresholds.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. (Pubmed Central) -  Mar 1, 2022   
    Treatment with high dose icosapent ethyl (IPE), an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA), significantly reduced ischemic events in patients with either cardiovascular disease (CV) or diabetes plus other risk factors (REDUCE-IT) but the mechanism is not well understood.  We compared the effects of EPA, docosahexaenoic acid (DHA), and the omega-6 fatty acid arachidonic acid (AA) on bioavailability of nitric oxide (NO) and fatty acid composition...AA alone decreased the EPA/AA ratio 4-fold (p<0.001). These findings support a preferential benefit of EPA on endothelial function and omega-3 fatty acid content.
  • ||||||||||  atorvastatin / Generic mfg., icosapent ethyl / Generic mfg.
    Vascepa and Lipitor (Twitter) -  Feb 19, 2022